Idorsia
Idorsia
IDIA
SIX
2.14
CHF
68.50%
About
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases.
The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 363.5K |
| Three Month Average Volume | 10.0M |
| High Low | |
| Fifty-Two Week High | 5.32 CHF |
| Fifty-Two Week Low | 1.294 CHF |
| Fifty-Two Week High Date | 04 Sep 2023 |
| Fifty-Two Week Low Date | 24 Jan 2024 |
| Price and Volume | |
| Current Price | 2.142 CHF |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -11.07% |
| Thirteen Week Relative Price Change | -20.32% |
| Twenty-Six Week Relative Price Change | -0.57% |
| Fifty-Two Week Relative Price Change | -60.46% |
| Year-to-Date Relative Price Change | -9.26% |
| Price Change | |
| One Day Price Change | -2.81% |
| Thirteen Week Price Change | -17.42% |
| Twenty-Six Week Price Change | 7.58% |
| Five Day Price Change | -5.64% |
| Fifty-Two Week Price Change | -55.80% |
| Year-to-Date Price Change | 1.32% |
| Month-to-Date Price Change | -16.13% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -5.41706 CHF |
| Book Value Per Share (Most Recent Quarter) | -5.79046 CHF |
| Tangible Book Value Per Share (Last Fiscal Year) | -5.43679 CHF |
| Tangible Book Value Per Share (Most Recent Quarter) | -5.8824 CHF |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.88961 CHF |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.85492 CHF |
| Revenue Per Share (Trailing Twelve Months) | 0.71438 CHF |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 CHF |
| Dividend Per Share (Trailing Twelve Months) | 0 CHF |
| Dividend Per Share (5 Year) | -99999.99 CHF |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.6714 CHF |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.1332 CHF |
| Normalized (Last Fiscal Year) | -2.72129 CHF |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.6714 CHF |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 0.1652 CHF |
| Including Extraordinary Items (Last Fiscal Year) | -1.6714 CHF |
| Including Extraordinary Items (Trailing Twelve Months) | -0.1332 CHF |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.88251 CHF |
| Cash Per Share (Most Recent Quarter) | 1.37749 CHF |
| Cash Flow Per Share (Last Fiscal Year) | -1.56439 CHF |
| Cash Flow Per Share (Trailing Twelve Months) | 0.26632 CHF |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.35553 CHF |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -789 |
| Cash Flow Revenue (Trailing Twelve Months) | -330 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 24.14% |
| Pretax Margin (Last Fiscal Year) | -193.10% |
| Pretax Margin (5 Year) | -705.45% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 95.31% |
| Gross Margin (Trailing Twelve Months) | 95.07% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -167.43% |
| Operating Margin (Trailing Twelve Months) | 43.27% |
| Operating Margin (5 Year) | -674.03% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -195.50% |
| Net Profit Margin (Trailing Twelve Months) | 22.42% |
| Net Profit Margin (5 Year) | -709.80% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -45.38% |
| Revenue Growth (3 Year) | 20.25% |
| Revenue Change (Trailing Twelve Months) | 1.62% |
| Revenue Per Share Growth | 12.27% |
| Revenue Growth (5 Year) | 28.54% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -8.01% |
| Total Debt (5 Year) | 14.65% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 20.32% |
| EPS Change (Trailing Twelve Months) | 97.09% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 883.4M |
| Net Debt (Last Fiscal Year) | 973.0M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 3 |
| Price to Sales (Trailing Twelve Months) | 3 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 13 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 12 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | 0.00% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 45 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -638,694,000 |
| Free Cash Flow (Trailing Twelve Months) | -421,522,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -16 |
| Net Interest Coverage (Trailing Twelve Months) | -20 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -42.43% |
| Return on Assets (Trailing Twelve Months) | 4.79% |
| Return on Assets (5 Year) | -46.72% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -5,490.36% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -63.90% |
| Return on Investment (Trailing Twelve Months) | 9.74% |
| Return on Investment (5 Year) | -53.84% |